WallStreetZenWallStreetZen

NASDAQ: KTTA
Pasithea Therapeutics Corp Stock

$7.60+0.30 (+4.11%)
Updated Feb 28, 2024
KTTA Price
$7.60
Fair Value Price
-$0.72
Market Cap
$7.92M
52 Week Low
$5.25
52 Week High
$17.40
P/E
-0.61x
P/B
0.28x
P/S
50.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$240.71k
Earnings
-$16.03M
Gross Margin
100.5%
Operating Margin
-6,657.21%
Profit Margin
-6,659.9%
Debt to Equity
0.08
Operating Cash Flow
-$14M
Beta
0.68
Next Earnings
Mar 30, 2024
Ex-Dividend
N/A
Next Dividend
N/A

KTTA Overview

Pasithea Therapeutics Corporation is a biotech company developing treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics was incorporated in 2020 and is headquartered in Miami Beach, FL.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KTTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

KTTA ($7.60) is overvalued by 1,162.54% relative to our estimate of its Fair Value price of -$0.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
KTTA ($7.60) is not significantly undervalued (1,162.54%) relative to our estimate of its Fair Value price of -$0.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KTTA due diligence checks available for Premium users.

Be the first to know about important KTTA news, forecast changes, insider trades & much more!

KTTA News

Valuation

KTTA fair value

Fair Value of KTTA stock based on Discounted Cash Flow (DCF)
Price
$7.60
Fair Value
-$0.72
Undervalued by
1,162.54%
KTTA ($7.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KTTA ($7.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KTTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

KTTA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.61x
Industry
13.96x
Market
35.52x

KTTA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.28x
Industry
6.14x
KTTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

KTTA's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.6M
Profit Margin
0%
KTTA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KTTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$30.7M
Liabilities
$2.3M
Debt to equity
0.08
KTTA's short-term assets ($20.77M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KTTA's short-term assets ($20.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KTTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.2M
Investing
$50.2k
Financing
-$3.9M
KTTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

KTTA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
KTTA$7.92M+4.11%-0.61x0.28x
BTTX$7.92M+1.21%-0.15x-0.80x
VCNX$7.82M+2.94%-0.10x-2.02x
TOVX$7.74M-1.30%-0.38x0.19x
CANF$7.64M-0.95%-0.69x1.11x

Pasithea Therapeutics Stock FAQ

What is Pasithea Therapeutics's quote symbol?

(NASDAQ: KTTA) Pasithea Therapeutics trades on the NASDAQ under the ticker symbol KTTA. Pasithea Therapeutics stock quotes can also be displayed as NASDAQ: KTTA.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.

What is the 52 week high and low for Pasithea Therapeutics (NASDAQ: KTTA)?

(NASDAQ: KTTA) Pasithea Therapeutics's 52-week high was $17.40, and its 52-week low was $5.25. It is currently -56.32% from its 52-week high and 44.65% from its 52-week low.

How much is Pasithea Therapeutics stock worth today?

(NASDAQ: KTTA) Pasithea Therapeutics currently has 1,041,831 outstanding shares. With Pasithea Therapeutics stock trading at $7.60 per share, the total value of Pasithea Therapeutics stock (market capitalization) is $7.92M.

Pasithea Therapeutics stock was originally listed at a price of $71.20 in Sep 15, 2021. If you had invested in Pasithea Therapeutics stock at $71.20, your return over the last 2 years would have been -89.33%, for an annualized return of -67.33% (not including any dividends or dividend reinvestments).

How much is Pasithea Therapeutics's stock price per share?

(NASDAQ: KTTA) Pasithea Therapeutics stock price per share is $7.60 today (as of Feb 28, 2024).

What is Pasithea Therapeutics's Market Cap?

(NASDAQ: KTTA) Pasithea Therapeutics's market cap is $7.92M, as of Feb 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pasithea Therapeutics's market cap is calculated by multiplying KTTA's current stock price of $7.60 by KTTA's total outstanding shares of 1,041,831.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.